Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism?

Alnylam Pharmaceuticals recently presented at Wells Fargo’s 21st Annual Healthcare Conference in Boston and Morgan Stanley’s 24th Annual Global Healthcare Conference in New York, highlighting its RNA interference portfolio to investors and industry peers. These appearances coincided with a very large projected expansion of the global oligonucleotide therapeutics market to US$72.10 billions by 2035, underscoring Alnylam’s positioning as a key RNA-based medicines innovator. We’ll now examine...